Notice of Application - 2003
FR Doc 03-2919
[Federal Register: February 6, 2003 (Volume 68, Number 25)]
[Notices]
[Page 6181-6182]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr06fe03-82]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of title 21 of the Code of Federal Regulations (CFR), this is notice that on October 23, 2002, AccuStandard, Inc., 125 Market Street, New Haven, Connecticut 06513, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:
| Drug |
Schedule |
| Cathinone (1235) |
I |
| Methcathinone (1237) |
I |
| Aminorex (1585) |
I |
| Gamma hydroxybutyric acid (2010) |
I |
| Metaqualone (2565) |
I |
| Ibogaine (7260) |
I |
| Lysergic acid diethylamide (7315) |
I |
| Tetrahydrocannabinols (7370) |
I |
| Mescaline (7381) |
I |
| 4-Bromo-2,5-dimethoxyamphetamine (7391) |
I |
| 4-Bromo-2,5-dimethoxyphenethylamine (7392) |
I |
| 4-Methyl-2,5-dimethoxyamphetamine (7395) |
I |
| 2,5-Dimethoxyamphetamine (7396) |
I |
| 3,4-Methylenedioxyamphetamine (7400) |
I |
| N-Hydroxy-3,4-methylenedioxyamphetamine (7402) |
I |
| 3,4-Methylenedioxy-N-ethylamphetamine (7404) |
I |
| 3,4-Methylenedioxymethamphetamine (7405) |
I |
| 4-Methoxyamphetamine (7411) |
I |
| Bufotenine (7433) |
I |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine (7470) |
I |
| Codeine-N-oxide (9053) |
I |
| Dihydromorphine (9145) |
I |
[[Page 6182]]
| Drug |
Schedule |
| Heroin (9200) |
I |
| Morphine-N-oxide (9307) |
I |
| Normorphine (9313) |
I |
| Etonitazene (9624) |
I |
| Amphetamine (1100) |
II |
| Methamphetamine (1105) |
II |
| Phenmetrazine (1631) |
II |
| Methylphenidate (1724) |
II |
| Amobarbital (2125) |
II |
| Pentobarbital (2270) |
II |
| Secobarbital (2315) |
II |
| Glutethimide (2550) |
II |
| Phencyclidine (7471) |
II |
| Alphaprodine (9010) |
II |
| Anileridine (9020) |
II |
| Cocaine (9041) |
II |
| Codeine (9050) |
II |
| Diprenorphine (9058) |
II |
| Dihydrocodeine (9120) |
II |
| Hydromorphone (9150) |
II |
| Diphenoxylate (9170) |
II |
| Benzoylecgonine (9180) |
II |
| Ecgonine (9180) |
II |
| Hydrocodone (9193) |
II |
| Levorphanol (9220) |
II |
| Methadone (9250) |
II |
| Morphine (9300) |
II |
| Thebaine (9333) |
II |
| Opium, raw (9600) |
II |
| Opium tincture (9630) |
II |
| Opium powdered (9639) |
II |
| Levo-alphacetylmethadol (9648) |
II |
| Oxymorphone (9652) |
II |
| Alfentanil (9737) |
II |
| Sufentanil (9740) |
II |
| Fentanyl (9801) |
II |
The firm plans to manufacture small quantities of the listed controlled substances to make reference standards.
Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.
Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register, Representative (CCR), and must be filed no later then April 7, 2003.
Dated: January 27, 2003.
Laura M. Nagel,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 03-2919 Filed 2-5-03; 8:45 am]
BILLING CODE 4410-09-M
NOTICE: This is an unofficial version. An official version of this publication may be obtained
directly from the Government Printing Office (GPO). |
